Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): three‐month interim analysis results
T Yamashita, Y Koretsune, M Ishikawa… - Journal of …, 2019 - Wiley Online Library
Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in
nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on …
nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on …
Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.
T Yamashita, Y Koretsune, M Ishikawa… - Journal of …, 2018 - europepmc.org
Background Direct oral anticoagulants are the first-line drugs for anticoagulation therapy in
nonvalvular atrial fibrillation (NVAF). However, a real-world, large-scale, clinical study on …
nonvalvular atrial fibrillation (NVAF). However, a real-world, large-scale, clinical study on …
Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
T Yamashita, Y Koretsune, M Ishikawa… - Journal of …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular …
Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in nonvalvular …
Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
T Yamashita, Y Koretsune, M Ishikawa… - Journal of …, 2019 - search.proquest.com
Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in
nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on …
nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on …
[HTML][HTML] Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
T Yamashita, Y Koretsune, M Ishikawa… - Journal of …, 2019 - ncbi.nlm.nih.gov
Background Direct oral anticoagulants are the first‐line drugs for anticoagulation therapy in
nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on …
nonvalvular atrial fibrillation (NVAF). However, a real‐world, large‐scale, clinical study on …
Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results
T Yamashita, Y Koretsune, M Ishikawa… - Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Direct oral anticoagulants are the first-line drugs for anticoagulation therapy in
nonvalvular atrial fibrillation (NVAF). However, a real-world, large-scale, clinical study on …
nonvalvular atrial fibrillation (NVAF). However, a real-world, large-scale, clinical study on …